BRAF and colorectal carcinoma: If the outcome of patients with BRAF mutation is so poor, then the natural history of MSIhi tumours lacking BRAF mutation must be even more favourable; a recent study of patients with operable stage II or stage III CRC made the same suggestion (French et al, 2008).